

# Financial Tear Sheet

## Corporate Profile

**MiMedx®** is an integrated developer, processor and marketer of patent protected and proprietary regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone.

**"Innovations in Regenerative Biomaterials"** is the framework behind our mission to give physicians products and tissues to help the body heal itself. The MiMedx allograft product families include our: dHACM family with AmnioFix®, EpiFix® and EpiBurn® brands; Amniotic Fluid family with OrthoFlo brand; Umbilical family with EpiCord™ and AmnioCord™ brands; Placental Collagen family with CollaFix™ and AmnioFill™ brands; Bone family with Physio® brand; and Skin family with AlloBurn™ brand. AmnioFix, EpiFix, and EpiBurn are our tissue technologies processed from human amniotic membrane; OrthoFlo is an amniotic fluid derived allograft; EpiCord™ and AmnioCord™ are derived from the umbilical cord; Physio is a unique bone grafting material comprised of 100% bone tissue with no added carrier; AlloBurn is a skin product derived from human skin designed for the treatment of burns; and CollaFix, our next brand we plan to commercialize, is our collagen fiber technology, developed with our patented cross-linking polymers, designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair. We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. MiMedx is the leading supplier of amniotic tissue, having supplied over 700,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare.

## Primary IR Contact

Michael J. Senken  
Chief Financial Officer  
MiMedx Group, Inc.

**Phone:** 770-651-9066

**E-mail:**

[investorrelations@mimedx.com](mailto:investorrelations@mimedx.com)

## Stock Performance

### MDXG (Common Stock)

Exchange	NASDAQ CM (US Dollar)
Price	<b>\$13.83</b>
Change (%)	<b>▲ 0.07 (0.51%)</b>
Volume	2,010,844
52 Week Low	\$7.64
Market Cap	\$1,555,460,515
Rolling EPS	0.19
PE Ratio	72.7895
Shares Outstanding	112,470,030

Data as of Oct 19, 2017 4:00 p.m. ET

■ MIMEDX GROUP INC  
as of 10/18/2017



EDGAROnline

## Recent Headlines & Events

Oct 18, 2017 - 3:30 p.m.

[New Clinical Evidence And A Landmark VLU Study To Be Presented At SAWC Fall Meeting](#)

Oct 17, 2017 - 9:01 a.m.

[MiMedx Warns Of Fake Emails](#)

Oct 17, 2017 - 7:30 a.m.

[MiMedx Notified By FDA That It Can Proceed With Phase 2B Investigational New Drug Clinical Trial For Osteoarthritis Of The Knee](#)

## SEC Filings

Filing Date	Form
Oct 11, 2017	<a href="#">8-K</a>
Oct 05, 2017	<a href="#">8-K</a>
Oct 02, 2017	<a href="#">8-K/A</a>
Sep 05, 2017	<a href="#">8-K</a>

Date

Title

Oct 27,  
2017 10:30  
a.m. ET

[Q3 2017 MIMEDX GROUP INC Earnings Conference Call](#)

## Corporate Governance

[Parker "Pete" H. Petit](#)

Chairman and Chief Executive Officer

[William C. Taylor](#)

President and Chief Operating Officer

[Michael J. Senken](#)

Chief Financial Officer

[Alexandra Haden](#)

General Counsel and Secretary

[Christopher M. Cashman](#)

EVP and Chief Commercialization Officer

[Deborah L. Dean](#)

Executive Vice President

[Thornton A. Kuntz](#)

Senior Vice President of Administration

[Michael W. Carlton](#)

Senior Vice President of Global Sales

[Marlene M. DeSimone](#)

Senior Vice President of Corporate Strategic Development

[Donald E. Fetterolf, M.D., FACP](#)

Chief Medical Officer

[Thomas J. Koob, PhD](#)

Chief Scientific Officer

[Frank Burrows](#)

Vice President of Clinical and Scientific Liaison

[Rebecca J. C. Brown, Ph.D.](#)

Vice President of Product Development

[Randall Spencer](#)

Vice President of Clinical Innovation

[David H. Mason, Jr., M.D.](#)

Vice President of Medical Affairs for Clinical Practice

I. Mark Landy

SVP Strategic Initiative

Powered By **EDGAR**Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed